$VRSK

LISS SAMUEL G sold $851K of VRSK

LISS SAMUEL G sold 4,671 shares of Verisk Analytics, Inc. (VRSK) at $182.21 ($0.85M total) on 2026-06-05.

Original reporting
SEC EDGAR · LISS SAMUEL G
Published Jun 8, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRSK
Neutral
medium confidence
Mentioned
$VRSK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale size, price, and that it was not under a pre-arranged 10b5-1 plan, which can influence sentiment but lacks fundamental context.

02

Market read

Traders may monitor for additional insider transactions or confirm whether this sale is part of a broader pattern; otherwise impact is likely modest.

03

What to watch

The filing doesn’t state tax, diversification, or personal liquidity needs; traders should compare with prior insider patterns and total insider net activity.

Relevance 5/10Novelty 8/10Timing: filed 2026-06-08 (sale dated 2026-06-05)

Background

The article is an SEC Form 4 insider transaction disclosure for Verisk Analytics, Inc.

Company-level read

Ticker impact

$VRSKNeutralMedium confidence
Context

Verisk director Liss Samuel G filed an open-market sale of 4,671 shares at $182.21 on 2026-06-05 (no 10b5-1 plan).

Expected impact

Likely limited, short-lived sentiment effect; watch for follow-on insider activity or unusual volume rather than expecting a sustained move.

Evidence & confidence

This is a primary SEC Form 4 disclosure, but the transaction is a single director sale and the article provides no accompanying operational/regulatory catalyst.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide signal.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity management; absence of a 10b5-1 plan doesn’t necessarily imply negative information.

Key entities

  • Verisk Analytics, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Liss Samuel G

    Director who sold 4,671 shares of VRSK on 2026-06-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer